. 2024 Nov 15;23:410. doi: 10.1186/s12933-024-02500-y

Table 2.

Two meta-analyses of large GLP-1RA clinical trials involving patients with diabetes at high cardiovascular risk

	Giugliano et al. [22] 2021	Sattar et al. [23] 2021
MACE	0.86 (0.79–0.94)	0.85 (0.80–0.90)
Cardiovascular death	0.87 (0.78–0.96)	0.85 (0.78–0.93)
MI	0.91 (0.81–1.01)	0.88 (0.81–0.96)
Stroke	0.84 (0.76–0.94)	0.81 (0.74–0.90)
HHF	0.90 (0.83–0.98)	0.88 (0.79–0.98)
All cause death	0.88 (0.80–0.96)	0.87 (0.81–0.94)
Composite kidney events*	0.83 (0.73–0.94)	0.79 (0.73–0.87)

Giugliano et al. [22] 2021

Sattar et al. [23] 2021

MACE

0.86

(0.79–0.94)

0.85

(0.80–0.90)

Cardiovascular death

0.87

(0.78–0.96)

0.85

(0.78–0.93)

0.91

(0.81–1.01)

0.88

(0.81–0.96)

Stroke

0.84

(0.76–0.94)

0.81

(0.74–0.90)

HHF

0.90

(0.83–0.98)

0.88

(0.79–0.98)

All cause death

0.88

(0.80–0.96)

0.87

(0.81–0.94)

Composite kidney events*

0.83

(0.73–0.94)

0.79

(0.73–0.87)

Data are presented as hazard ratio (95% confidence interval)

GLP-1RA glucagon-like peptide-1 receptor agonist, HHF heart failure hospitalization, MACE major adverse cardiovascular events, MI myocardial infarction

*Including macroalubuminuria